PMID- 36629486
OWN - NLM
STAT- MEDLINE
DCOM- 20230209
LR  - 20230301
IS  - 1744-8336 (Electronic)
IS  - 1478-7210 (Linking)
VI  - 21
IP  - 2
DP  - 2023 Feb
TI  - The efficacy and safety of ceftolozane-tazobactam in the treatment of GNB 
      infections: a systematic review and meta-analysis of clinical studies.
PG  - 189-201
LID - 10.1080/14787210.2023.2166931 [doi]
AB  - BACKGROUND: Ceftolozane-tazobactam is a novel cephalosporin/beta-lactamase inhibitor 
      combination with activity against Gram-negative bacteria (GNB). We aimed to 
      comprehensively evaluate the clinical efficacy and safety of 
      ceftolozane-tazobactam in treating GNB infections in adult patients. RESEARCH 
      DESIGN AND METHODS: PubMed, Embase, and Cochrane databases were retrieved until 
      August 2022. Randomized trials and non-randomized controlled studies evaluating 
      ceftolozane-tazobactam and its comparators in adult patients with GNB infections 
      were included. RESULTS: A total of 13 studies were included. Overall, patients 
      receiving ceftolozane-tazobactam had significant advantages in clinical cure 
      (odds ratio [OR], 1.62; 95% CI, 1.05-2.51) and microbiological eradication (OR, 
      1.43; 95% CI, 1.19-1.71), especially in Pseudomonas aeruginosa-infected patients. 
      Ceftolozane-tazobactam had a significant advantage in clinical success or 
      microbial eradication compared with polymyxin/aminoglycosides (PL/AG) or 
      levofloxacin. There were no significant differences in adverse events (AEs), 
      Clostridium difficile infection (CDI), and mortality between 
      ceftolozane-tazobactam and comparators. Notably, ceftolozane-tazobactam showed a 
      significantly lower risk of acute kidney injury compared with PL/AG. CONCLUSIONS: 
      Ceftolozane-tazobactam showed excellent clinical and microbiological efficacy in 
      treating GNB, especially P. aeruginosa-induced infections. The overall safety 
      profile of ceftolozane-tazobactam was comparable to other antimicrobials, with no 
      increased risk of CDI and obvious advantage over antibacterial agents with high 
      nephrotoxicity.
FAU - Chi, Yulong
AU  - Chi Y
AD  - Center of Medicine Clinical Research, Department of Pharmacy, Medical Supplies 
      Center, Chinese PLA General Hospital, Beijing, China.
AD  - Graduate School of Chinese PLA General Hospital, Beijing, China.
FAU - Xu, Juan
AU  - Xu J
AD  - Center of Medicine Clinical Research, Department of Pharmacy, Medical Supplies 
      Center, Chinese PLA General Hospital, Beijing, China.
FAU - Bai, Nan
AU  - Bai N
AD  - Center of Medicine Clinical Research, Department of Pharmacy, Medical Supplies 
      Center, Chinese PLA General Hospital, Beijing, China.
FAU - Liang, Beibei
AU  - Liang B
AD  - Center of Medicine Clinical Research, Department of Pharmacy, Medical Supplies 
      Center, Chinese PLA General Hospital, Beijing, China.
FAU - Cai, Yun
AU  - Cai Y
AD  - Center of Medicine Clinical Research, Department of Pharmacy, Medical Supplies 
      Center, Chinese PLA General Hospital, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20230119
PL  - England
TA  - Expert Rev Anti Infect Ther
JT  - Expert review of anti-infective therapy
JID - 101181284
RN  - 0 (Aminoglycosides)
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (ceftolozane, tazobactam drug combination)
RN  - 0 (Cephalosporins)
RN  - 0 (Monobactams)
RN  - 0 (Polymyxins)
RN  - SE10G96M8W (Tazobactam)
SB  - IM
MH  - Adult
MH  - Humans
MH  - Aminoglycosides
MH  - Anti-Bacterial Agents/adverse effects/therapeutic use
MH  - *Cephalosporins/adverse effects/therapeutic use
MH  - Gram-Negative Bacteria
MH  - *Gram-Negative Bacterial Infections/drug therapy
MH  - Microbial Sensitivity Tests
MH  - Monobactams
MH  - Polymyxins
MH  - Pseudomonas aeruginosa
MH  - *Pseudomonas Infections/drug therapy
MH  - *Tazobactam/adverse effects/therapeutic use
OTO - NOTNLM
OT  - Ceftolozane-tazobactam
OT  - Gram-negative bacteria
OT  - Pseudomonas aeruginosa
OT  - efficacy
OT  - meta-analysis
OT  - safety
EDAT- 2023/01/12 06:00
MHDA- 2023/02/09 06:00
CRDT- 2023/01/11 09:23
PHST- 2023/01/12 06:00 [pubmed]
PHST- 2023/02/09 06:00 [medline]
PHST- 2023/01/11 09:23 [entrez]
AID - 10.1080/14787210.2023.2166931 [doi]
PST - ppublish
SO  - Expert Rev Anti Infect Ther. 2023 Feb;21(2):189-201. doi: 
      10.1080/14787210.2023.2166931. Epub 2023 Jan 19.